Defactinib and Avutometinib, With or Without Encorafenib, for the Treatment of Patients With Brain Metastases From Cutaneous Melanoma

PHASE1/PHASE2RecruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

March 7, 2024

Primary Completion Date

January 15, 2028

Study Completion Date

January 15, 2030

Conditions

Melanoma

Interventions

DRUG

Defactinib

Defactinib will be administered at 200 mg twice daily orally per arm description.

DRUG

Avutometinib

Avutometinib will be administered at 3.2 mg twice a week orally per arm description.

DRUG

Encorafenib

Encorafinib administered orally per arm description.

Trial Locations (2)

RECRUITING

University of Iowa, Iowa City

RECRUITING

Huntsman Cancer Institute, Salt Lake City

All Listed Sponsors

collaborator

Verastem, Inc.

INDUSTRY

lead

University of Utah

OTHER